Gilead Sciences Stock Fundamentals
| GILD Stock | USD 89.76 1.13 1.27% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
At present, Gilead Sciences' Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 20.5 B, whereas Interest Expense is forecasted to decline to about 534.5 M. Gilead | Select Account or Indicator |
Gilead Sciences Company Profit Margin Analysis
Gilead Sciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Gilead Sciences Profit Margin | 0 % |
Most of Gilead Sciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Gilead Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Gilead Sciences has a Profit Margin of 0.0045%. This is 100.04% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 100.35% lower than that of the firm.
Gilead Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gilead Sciences competition to find correlations between indicators driving Gilead Sciences's intrinsic value. More Info.Gilead Sciences is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 21.36 of Return On Asset per Return On Equity. At present, Gilead Sciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Gilead Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is currently under evaluation in profit margin category among its peers.
Gilead Sciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gilead Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gilead Sciences' managers, analysts, and investors.Environmental | Governance | Social |
Gilead Fundamentals
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 128.67 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 88.21 % | ||||
| Number Of Shares Shorted | 17.74 M | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 5.98 X | ||||
| Price To Sales | 3.90 X | ||||
| Revenue | 27.12 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 7.61 B | ||||
| Net Income | 5.61 B | ||||
| Cash And Equivalents | 6.14 B | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 24.99 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 14.83 X | ||||
| Cash Flow From Operations | 8.01 B | ||||
| Short Ratio | 3.50 X | ||||
| Earnings Per Share | 0.09 X | ||||
| Price To Earnings To Growth | 0.52 X | ||||
| Target Price | 96.92 | ||||
| Number Of Employees | 18 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 110.46 B | ||||
| Total Asset | 62.12 B | ||||
| Retained Earnings | 16.3 B | ||||
| Working Capital | 4.8 B | ||||
| Current Asset | 1.18 B | ||||
| Current Liabilities | 104.89 M | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.76 % | ||||
| Net Asset | 62.12 B | ||||
| Last Dividend Paid | 3.06 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.1 B | -2 B | |
| Total Revenue | 27.1 B | 28.5 B | |
| Cost Of Revenue | 5.8 B | 6.1 B | |
| Stock Based Compensation To Revenue | 0.03 | 0.03 | |
| Sales General And Administrative To Revenue | 0.19 | 0.30 | |
| Research And Ddevelopement To Revenue | 0.26 | 0.24 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 21.73 | 22.81 | |
| Ebit Per Revenue | 0.28 | 0.29 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Gilead Sciences Piotroski F Score and Gilead Sciences Altman Z Score analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.